Skip to main content

Advertisement

Table 5 Parameters from ROC analysis on serum Trx1, CEA, and CA15-3 levels in patients with breast cancer

From: Thioredoxin 1 as a serum marker for breast cancer and its use in combination with CEA or CA15-3 for improving the sensitivity of breast cancer diagnoses

BC Grade AUC* (±SEM) Sensitivity (%) Specificity (%) Criterion** Value # of serum (# of L:-D) §
BC_Total 0.901 ± 0.0252 89.8 78.0 >32.1725 197 (106:91)
0.678 ± 0.0408 54.4 77.6 >8.28
0.179 ± 0.0359 48.6 89.8 >29.8227
BC I 0.837 ± 0.0399 89.4 72.0 - 66 (35:31)
0.594 ± 0.0523 30.3 89.8 -
0.693 ± 0.0482 50.0 83.7 -
BC II 0.908 ± 0.0270 82.9 86.0 - 70 (37:33)
0.692 ± 0.0478 56.8 77.6 -
0.673 ± 0.0480 44.8 89.8 -
BC III 0.962 ± 0.0156 88.5 92.0 - 61 (34:27)
0.762 ± 0.0460 66.7 77.6 -
0.794 ± 0.0411 60.6 89.8 -
Normal - - - - 50 (NF)
  1. *P < 0.0001.
  2. **Units of criterion values represent as ng/ml for Trx1 and CEA or U/ml for CA15-3.
  3. Upper, middle, and lower values in each row are those for Trx1, CEA, and CA 15–3, respectively.
  4. §L and D are lobular and ductal carcinoma of breast cancer respectively.